2,135 Shares in TransMedics Group, Inc. $TMDX Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,135 shares of the company’s stock, valued at approximately $286,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Opal Wealth Advisors LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $26,000. Sound Income Strategies LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $48,000. Smartleaf Asset Management LLC lifted its stake in shares of TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Quarry LP lifted its stake in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC lifted its stake in shares of TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after purchasing an additional 205 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMDX has been the topic of several analyst reports. Evercore ISI assumed coverage on TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price on the stock. Morgan Stanley boosted their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Stifel Nicolaus assumed coverage on TransMedics Group in a research report on Thursday, September 4th. They set a “hold” rating and a $115.00 price target on the stock. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $130.73.

TransMedics Group Trading Up 1.2%

Shares of TransMedics Group stock opened at $130.52 on Friday. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 67.63 and a beta of 2.08. The business has a fifty day simple moving average of $115.94 and a 200-day simple moving average of $115.23. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $145.50.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the prior year, the firm posted $0.35 earnings per share. The company’s revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.